Furthermore, IL13Rα2 expression in glioblastoma has been associated with an increased malignancy grade, the aggressive mesenchymal gene expression signature, and higher IL13Rα2 expression has been correlated with a poorer patient prognosis17, all of which suggest that treatment approaches that can specifically target IL13Rα2-expressing glioma cells could improve outcomes for patients with a particularly aggressive tumor phenotype. The gene discussed is IL13RA2; the disease is neoplasm.